AKTi-1/2 (AKT Inhibitor VIII)

AKTi-1/2 (AKT Inhibitor VIII) is an inhibitor of AKT1 and AKT2 and related targets used in studies of PI3K-Akt-mTOR Signaling and Apoptosis. It is especially relevant in apoptosis, cancer, and cell signaling models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs and caspase-associated cell-death signaling and survival decisions.

By inhibiting AKT1 and AKT2 and related targets, AKTi-1/2 (AKT Inhibitor VIII) can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving AKT1 and AKT2 and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Apoptosis
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, AKTi-1/2 (AKT Inhibitor VIII) is appropriate when a defined chemical perturbant is needed to connect AKT1 and AKT2 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.